Analysis of Genes Present in Cutaneous T-cell Lymphoma Cells

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically proven mycosis fungoides with 2 or more plaques or tumors greater than 1 cm in size OR
• •Immunologically proven Sezary syndrome with all of the following:
• •* Erythroderma
• •* Lymphadenopathy
• •* T-cell receptor variable beta chain clonality greater than 10% of total lymphocytes by flow cytometry OR
• •* CD4+CD7- T-cell fraction that represents greater than 10% of CD4+ T cells
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 to 85
• •Performance status:
• •Not specified
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •See Disease Characteristics
• •Hepatic:
• •Not specified
• •Renal:
• •Not specified
• •Other:
• •Not pregnant or nursing
• •HIV-1 and HTLV-1 negative
• •No prior intravenous drug use
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Not specified
• •Chemotherapy:
• •At least 2 months since prior systemic chemotherapy
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •At least 2 months since prior electron beam radiotherapy
• •Surgery:
• •Not specified
• •Other:
• •At least 2 weeks since prior topical therapy
• •At least 2 months since prior photopheresis
• •At least 2 months since prior psoralen ultraviolet light (PUVA) or ultraviolet B (UVB) therapy